Drug intelligence / Profile preview

JNJ-41443532

Development stage: Phase 2
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

JNJ-41443532 is an investigational small molecule drug developed for the treatment of type 2 diabetes mellitus. It acts as an oral antagonist of the C-C motif chemokine receptor 2 (CCR2), a receptor involved in macrophage recruitment to adipose tissue, which is believed to contribute to insulin resistance and the pathogenesis of type 2 diabetes. Clinical studies have shown that administration of JNJ-41443532 results in modest improvements in glycemic parameters and is generally well tolerated. The drug was developed by Johnson & Johnson Pharmaceutical Research & Development and Janssen Research & Development, but development has not progressed beyond phase II clinical trials[1][2][3][4][5][6].

Other names: 1228650-83-6

Targets

CCR2 (Chemokine (C-C motif) Receptor 2)

Beyond the preview

Go deeper on JNJ-41443532.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-41443532.

Explore the full profile